Literature DB >> 23941822

Antineutrophil cytoplasmic antibody vasculitis associated with influenza vaccination.

Tanu Duggal1, Paul Segal, Megha Shah, Naima Carter-Monroe, Pradeep Manoharan, Duvuru Geetha.   

Abstract

BACKGROUND: Administration of influenza vaccines has been associated with the development of autoantibodies and autoimmune rheumatic disease. PATIENTS: We discuss 2 patients who developed antineutrophil cytoplasmic antibody-associated vasculitis (AAV) in temporal association with influenza immunization. AAV was diagnosed 2 and 4 weeks after immunization in these patients. Both patients had renal involvement with one requiring dialysis. Both patients were treated with cyclophosphamide and corticosteroids, and plasmapheresis was added to the immunosuppressive regimen in one patient with dialysis-dependent renal failure. Both patients achieved disease remission. The patient with initial dialysis-dependent renal failure reached end-stage renal disease. There are 6 previous cases of AAV in the literature described in temporal association with administration of influenza vaccines.
CONCLUSION: A causal role of vaccines in AAV cannot be confirmed with these case reports. The temporality suggests that the influenza vaccine may be a triggering factor for induction of vasculitis in predisposed individuals. We review the literature on reported cases of AAV following influenza vaccine administration and discuss possible mechanisms for influenza vaccine-associated AAV.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23941822     DOI: 10.1159/000354084

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  12 in total

Review 1.  Prophylactic vaccinations in chronic kidney disease: Current status.

Authors:  Alicja E Grzegorzewska
Journal:  Hum Vaccin Immunother       Date:  2015-04-27       Impact factor: 3.452

Review 2.  Vasculitis for the internist: focus on ANCA-associated vasculitis.

Authors:  Benjamin Chaigne; Loïc Guillevin
Journal:  Intern Emerg Med       Date:  2017-06-16       Impact factor: 3.397

3.  Microscopic Polyangiitis Following mRNA COVID-19 Vaccination: A Case Report.

Authors:  Daeyoung So; Kyueng-Whan Min; Woon Yong Jung; Sang-Woong Han; Mi-Yeon Yu
Journal:  J Korean Med Sci       Date:  2022-05-16       Impact factor: 5.354

4.  Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling.

Authors:  Chao-Hung Chen; Yu-Jen Lin; Li-Ting Cheng; Chien-Hung Lin; Guan-Ming Ke
Journal:  Vaccines (Basel)       Date:  2022-05-02

5.  Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation.

Authors:  Lisa S Jeffs; Jodie Nitschke; Jan Willem Cohen Tervaert; Chen Au Peh; Plinio R Hurtado
Journal:  Clin Rheumatol       Date:  2015-09-12       Impact factor: 2.980

6.  A Case of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Post COVID-19 Vaccination.

Authors:  Zaki Al-Yafeai; Benjamin Joesph M Horn; William Terraccaine; Alvin Jose; Prathik Krishnan
Journal:  Cureus       Date:  2022-03-14

7.  MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination.

Authors:  Stefanie Eindhoven; Jolien Levels; Margriet Huisman; Koos Ruizeveld de Winter; Virgil Dalm; Rehmat Alwani
Journal:  Allergy Asthma Clin Immunol       Date:  2017-12-13       Impact factor: 3.406

8.  Vaccine: friend or foe? Double seropositive vasculitis following influenza vaccination.

Authors:  Benjamin Norton; Sui Phin Kon; Ranmith Perera; Richard Hull
Journal:  Oxf Med Case Reports       Date:  2019-05-31

Review 9.  Vaccines, adjuvants and autoimmunity.

Authors:  Luísa Eça Guimarães; Britain Baker; Carlo Perricone; Yehuda Shoenfeld
Journal:  Pharmacol Res       Date:  2015-08-12       Impact factor: 7.658

10.  New-onset leukocytoclastic vasculitis after COVID-19 vaccine.

Authors:  Ecem Bostan; Duygu Gulseren; Ozay Gokoz
Journal:  Int J Dermatol       Date:  2021-07-09       Impact factor: 3.204

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.